Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 9/30/2020 | 6/30/2020 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $6 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $56 | $66 | $49 | $47 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $422 | $323 | $194 | $106 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $600 | $0 | -$600 | $0 |
| Operating Expenses | $1,078 | $389 | -$357 | $153 |
| Operating Income | -$1,078 | -$389 | -$243 | -$153 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $588 | -$13 | $651 | -$16 |
| Pre-Tax Income | -$490 | -$401 | $408 | -$169 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$443 | -$361 | $436 | -$150 |
| % Margin | – | – | – | – |
| EPS | -0.019 | -0.015 | 0.03 | -0.01 |
| % Growth | -26% | -150% | 400% | – |
| EPS Diluted | -0.019 | -0.015 | 0.004 | -0.01 |
| Weighted Avg Shares Out | 24,116 | 24,449 | 15,024 | 14,489 |
| Weighted Avg Shares Out Dil | 24,116 | 24,449 | 19,469 | 14,489 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $13 | $13 | $16 | $16 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | -$476 | -$388 | $424 | -$152 |
| % Margin | – | – | – | – |